Literature DB >> 1280125

Omeprazole, an inducer of human CYP1A1 and 1A2, is not a ligand for the Ah receptor.

M Daujat1, B Peryt, P Lesca, G Fourtanier, J Domergue, P Maurel.   

Abstract

Omeprazole is a benzimidazole derivative which induces both P450 1A1 and 1A2 in human liver in vitro and in vivo. Northern blot analysis of polyA RNA prepared from primary cultures of human hepatocytes indicates that both 1A1 and 1A2 messages are induced by beta-naphthoflavone and omeprazole. Co-treatment of cells with these inducers and with actinomycin D or cycloheximide results in no accumulation of both mRNA or superinduction of 1A1 mRNA, respectively. 9S enriched fraction of cytosol was prepared either from human hepatocytes in culture or from human liver tissue and analyzed by sucrose density gradient sedimentation for its capacity to bind 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), omeprazole or omeprazole sulfone (a metabolite of omeprazole in man). Whereas 2 microM TCDD displaced almost totally [3H]TCDD from the Ah receptor, both omeprazole and omeprazole sulfone did not, even at 5000-fold molar excess. In addition, when [14C] omeprazole was incubated with 9S enriched fraction of human liver or hepatocyte cytosol, no interaction could be detected in sucrose density gradient. These experiments suggest that omeprazole is not a ligand for the human liver Ah receptor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280125     DOI: 10.1016/0006-291x(92)91130-i

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

Review 1.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 2.  Mechanisms of xenobiotic receptor activation: Direct vs. indirect.

Authors:  Bryan Mackowiak; Hongbing Wang
Journal:  Biochim Biophys Acta       Date:  2016-02-10

Review 3.  On the general mechanism of selective induction of cytochrome P450 enzymes by chemicals: some theoretical considerations.

Authors:  Bao Ting Zhu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-04       Impact factor: 4.481

Review 4.  Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.

Authors:  U A Meyer
Journal:  Yale J Biol Med       Date:  1996 May-Jun

Review 5.  The search for endogenous activators of the aryl hydrocarbon receptor.

Authors:  Linh P Nguyen; Christopher A Bradfield
Journal:  Chem Res Toxicol       Date:  2007-12-13       Impact factor: 3.739

Review 6.  Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical.

Authors:  Michael Sinz; Gillian Wallace; Jasminder Sahi
Journal:  AAPS J       Date:  2008-08-07       Impact factor: 4.009

7.  Omeprazole induces NAD(P)H quinone oxidoreductase 1 via aryl hydrocarbon receptor-independent mechanisms: Role of the transcription factor nuclear factor erythroid 2-related factor 2.

Authors:  Shaojie Zhang; Ananddeep Patel; Bhagavatula Moorthy; Binoy Shivanna
Journal:  Biochem Biophys Res Commun       Date:  2015-10-09       Impact factor: 3.575

8.  Omeprazole stimulates the induction of human insulin-like growth factor binding protein-1 through aryl hydrocarbon receptor activation.

Authors:  Iain A Murray; Gary H Perdew
Journal:  J Pharmacol Exp Ther       Date:  2007-11-30       Impact factor: 4.030

9.  Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam.

Authors:  Dustyn A Barnette; Mary A Schleiff; Arghya Datta; Noah Flynn; S Joshua Swamidass; Grover P Miller
Journal:  Toxicol Lett       Date:  2020-11-27       Impact factor: 4.372

10.  AhR activation underlies the CYP1A autoinduction by A-998679 in rats.

Authors:  Michael J Liguori; Chih-Hung Lee; Hong Liu; Rita Ciurlionis; Amy C Ditewig; Stella Doktor; Mark E Andracki; Gerard D Gagne; Jeffrey F Waring; Kennan C Marsh; Murali Gopalakrishnan; Eric A G Blomme; Yi Yang
Journal:  Front Genet       Date:  2012-10-26       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.